Wake up -- it's Monday. 

Let's go:

ETF Inflows

The runaway growth of exchange-traded funds over the past decade shows no signs of abating. A top industry forecaster is projecting assets will surge at least 18% this year, topping $4 trillion for the first time, wrote TheStreet's Bradley Keoun

Deborah Fuhr, managing partner at the London-based consultancy ETFGI, said new regulations expected this year from the Securities and Exchange Commission will make it easier for big purveyors like BlackRock Inc., State Street Corp. and competitors in the money-management industry to issue new ETFs.

Spark Therapeutics

Spark Therapeutics Inc. (ONCE) - Get Report shares more than doubled Monday after the gene therapy specialist agreed to a $4.3 billion takeover by Switzerland-based Roche Holding (RHHBY) , the world's biggest maker of cancer treatments, wrote TheStreet's Martin Baccardax.

Roche said it will pay $114.50 per share for Spark, a 122% premium to the stock's Friday close price that would value the Philadelphia, Pa.-based biotech and its portfolio of neuro-degenerative disease treatments -- including Luxturna -- at around $4.3 billion.

Palo Alto

U.S. stocks are getting another boost on Monday after positive trade commentary between the U.S. and China, wrote TheStreet's Bret Kenwell. Along with the rally, Palo Alto Networks (PANW) - Get Report  is up about 1.3% in midday trading to $233 following some bullish analyst commentary.

Palo Alto Networks stock didn't just get a price target boost to $275 from $256 by the analysts at Guggenheim, but it was also named a Top Pick at the firm. The price target implies 19.5% upside from Palo Alto's closing price on Friday and is the second-highest target on the Street, just behind Maxim Group's $280 price target.